Combinatorial Phenotypic Signatures Distinguish Persistent from Resolving Methicillin-Resistant Staphylococcus aureus Bacteremia Isolates
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia (PB) (positive blood cultures after ≥7 days of therapy) represents a clinically challenging subset of invasive MRSA infections. In this investigation, we examined the potential correlation of specific virulence signatures with PB versus resolving MRSA bacteremia (RB) (negative blood cultures within 2 to 4 days of therapy) strains. Thirty-six MRSA isolates from patients enrolled in a recent multinational clinical trial were studied for (i) susceptibility to host defense cationic peptides (HDPs) (i.e., thrombin-induced platelet microbicidal proteins [tPMPs] and human neutrophil peptide 1 [hNP-1]); (ii) adherence to host endovascular ligands (fibronectin) and cells (endothelial cells); and (iii) biofilm formation. We found that PB isolates exhibited significantly reduced susceptibilities to tPMPs and hNP-1 ( P < 0.001 and P = 0.023, respectively). There was no significant association between the PB outcome and fibronectin binding, endothelial cell binding, or biofilm formation ( P = 0.25, 0.97, and 0.064 versus RB strains, respectively). However, multiple logistic regression analysis revealed that the PB outcome was significantly associated with the combination of reduced susceptibilities to HDPs and extent of biofilm formation ( P < 0.0001). Similar results were obtained in a second analysis using days of bacteremia as a continuous outcome, showing that reduced HDP susceptibilities and increased biofilm formation cocontributed to predict the duration of bacteremia. Our data indicate that PB isolates have specific pathogenic signatures independent of conventional antimicrobial susceptibility. These combinatorial mosaics can be defined and used to prospectively distinguish PB from RB strains in advance and potentially to predict ultimate clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Staphylococcus aureus is a leading cause of bacteremia and infective endocarditis (IE) throughout the industrialized world (18, 22, 42, 54).”
BackgroundStaphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Self-citationMolecular Koch's Postulates Applied to Microbial Pathogenicity
Falkow, S. (1988) · Clinical Infectious Diseases · doi:10.1093/cid/10.supplement_2.s274 · Cited by 655
Levine, D. P., Fromm, B. S., & Reddy, B. R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-9-674 · Cited by 577
Izano, E. A., Amarante, M. A., Kher, W. B., & Kaplan, J. B. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.02073-07 · Cited by 553 · cited 2×
“incubated for 2 h at 37°C as previously described (30, 50, 53).”
BackgroundMethodFluit, A. C., Jones, M. E., Schmitz, F.-J., Acar, J., Gupta, R., Verhoef, J., & the SENTRY Participants Group (2000) · Clinical Infectious Diseases · doi:10.1086/313710 · Cited by 312
Fowler, Jr., Sanders, L. L., Kong, L. K., McClelland, R. S., Gottlieb, G. S., Li, J., Ryan, T., Sexton, D. J., Roussakis, G., Harrell, L. J., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515076 · Cited by 196 · cited 1×
“aureus bacteremia led us to examine the ability of the PB versus RB cohorts to form biofilms in vitro (12, 19, 21, 28, 34).”
BackgroundPenetration and damage of endothelial cells by Candida albicans
Filler, S. G., Swerdloff, J. N., Hobbs, C., & Luckett, P. M. (1995) · Infection and Immunity · doi:10.1128/iai.63.3.976-983.1995 · Cited by 184
LaPlante, K. L., & Woodmansee, S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00134-09 · Cited by 110
Cited by
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Staphylococcal Biofilm Development: Structure, Regulation, and Treatment Strategies
Schilcher, K., & Horswill, A. R. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00026-19 · Cited by 706
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Self-citationMoellering, R. C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr437 · Cited by 236
Sakoulas, G., Bayer, A. S., Pogliano, J., Tsuji, B. T., Yang, S.-J., Mishra, N. N., Nizet, V., Yeaman, M. R., & Moise, P. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05551-11 · Cited by 176
“It is also conceivable that ampicillin may affect biofilm formation in vivo, which may also have played a role in the clearance of bacteremia, given the importance of this phenotype in endocarditis and persistent bacteremia (38).”
BackgroundSelf-citation
Metadata
- Authors
- Seidl, K., Bayer, A. S., Fowler, V. G., McKinnell, J. A., Abdel Hady, W., Sakoulas, G., Yeaman, M. R., & Xiong, Y. Q.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-02
- Volume
- 55
- Issue
- 2
- Pages
- 575-582
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2145862457
- Cited by
- 69
- References
- 9
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.